11: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development - Part 1

Dive into the world of cell therapy process development with Steve Oh, former Institute Professor at the Bioprocessing Technology Institute (BTI) at the Agency for Science and Technology (A*STAR) and now Scientific Advisor to several international companies, as he shares thought-provoking perspectives and predictions on technologies that will impact the biotech industry.In this riveting conversation, Steve Oh unveils secrets to consistent bioproducts and forecasts the future of cell and gene therapy.Gain a deeper understanding of the evolving landscape and the challenges and opportunities it presents.Key Takeaways:The Power of Open Mindsets: Discover why carefully orchestrated listening ears lay the foundation for developing solutions in bioprocess development. Learn how avoiding predetermined views enhances the quality of conversations.Beyond Short-Term Goals: Uncover the downside of short-term thinking and how prioritizing long-term improvements can lead to substantial productivity gains. Steve delves into the balance between meeting financial deliverables and achieving lasting advancements.Process Development as a Pillar: Gain insights into why process development is a critical pillar in every biotech company's journey towards scaling. Steve emphasizes the significance of manufacturing consistent biological products and the need to educate scientists on the process's pivotal role.Join the conversation as Steve Oh unfolds the intricate world of cell therapy process development, offering a roadmap from lab exploration to patient impact.Currently, Steve is an Scientific Advisor to several international companies involved in lentivirus & AAV manufacturing, cryopreservation solutions, biodegradable/edible microcarriers, novel gene delivery methods, cultured meat and stem cell manufacturing.Connect with Steve Oh:LinkedIn: https://www.linkedin.com/in/steve-oh-4946261/One bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.Support the show